Comparative Pharmacology
Head-to-head clinical analysis: ALOMIDE versus CROMOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOMIDE versus CROMOPTIC.
ALOMIDE vs CROMOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
1 to 2 drops in each affected eye four times daily (every 6 hours).
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer